Pulmo BioTech, Inc. (OTC:PLMO) has announced that the early experimental results of its PulmoBind product can potentially detect and follow up many conditions affecting the physical and or biological integrity of the Pulmonary Circulation. The results are early. If further experiments confirm the products ability to detect medical conditions, the product will be used to diagnose a wide variety of medical conditions.
Best Damn Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Stock Newsletter
Formerly Acorn Acquisition Corp, Pulmo Bio Tech, Inc. was primarily engaged in the oil and gas industry. PLMO merged with Lumen Medical Inc on February 29, 2008. The company had no revenues during the fiscal year ended March 31, 2009.
Sign up for the free Best Damn Penny Stocks newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website
About Us
Best Damn Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer
